Reviva Pharmaceuticals Holdings Inc (RVPH)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.34-10.53%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · RVPH
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
After FDA feedback, we plan to initiate a bioequivalence study to confirm comparability of the new formulation in the fourth quarter of this year and intend to initiate patient enrollment in our RECO…
Stated in 1 of 1 supplied quarters. Management reported: “After FDA feedback, we plan to initiate a bioequivalence study to confirm comparability of the new formulation in the fourth quarter of this year and intend to initiate patient enrollment in our RECOVER-2 trial in the first half of 2027 subject to receipt of additional financing.” “In parallel, we are preparing to initiate RECOVER-2, our registrational Phase 3 trial in schizophrenia, with patient enrollment expected to begin in the third quarter of 2026.” Net income was $-2.448 million in 2026-Q2.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 3 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“After FDA feedback, we plan to initiate a bioequivalence study to confirm comparability of the new formulation in the fourth quarter of this year and intend to initiate patient enrollment in our RECO…”
“We are seeking accelerated review of our composition of matter patent application for a new form of brilaroxazine, which we believe can meaningfully extend patent life and commercial exclusivity for…
Stated in 1 of 1 supplied quarters. Management reported: ““We are seeking accelerated review of our composition of matter patent application for a new form of brilaroxazine, which we believe can meaningfully extend patent life and commercial exclusivity for the program through 2046.” ““A key priority is to incorporate a new form of brilaroxazine into our clinical and regulatory pathway, which we believe has the potential to extend patent protection and commercial exclusivity of the program.”
““We are seeking accelerated review of our composition of matter patent application for a new form of brilaroxazine, which we believe can meaningfully extend patent life and commercial exclusivity for…”
“We continue to advance our clinical development and regulatory strategy for brilaroxazine while managing our capital resources carefully,” said Laxminarayan Bhat, Founder, President, and CEO of Revi…
Stated in 1 of 1 supplied quarters. Management reported: ““We continue to advance our clinical development and regulatory strategy for brilaroxazine while managing our capital resources carefully,” said Laxminarayan Bhat, Founder, President, and CEO of Reviva.” “● Completed public equity offering in March 2026, raising gross proceeds of $10.0 million, before deducting placement agent fees and other offering expenses.”
““We continue to advance our clinical development and regulatory strategy for brilaroxazine while managing our capital resources carefully,” said Laxminarayan Bhat, Founder, President, and CEO of Revi…”
Seek FDA feedback on using the new brilaroxazine formulation in RECOVER-2 and a future NDA submission.
Continue pursuing potential partnerships for development of the company's pipeline.
Over the trailing year it converted 1.23x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
15 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.